{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:46:07Z","timestamp":1790646367575,"version":"4.1.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Circ"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/2394-8108.192519","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T01:44:52Z","timestamp":1476755092000},"page":"133","source":"Crossref","is-referenced-by-count":13,"title":["Creatine supplementation improves neural progenitor cell survival in Huntington's disease"],"prefix":"10.4103","volume":"2","author":[{"given":"HansR","family":"Widmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RobertH","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Wallimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2394-8108.192519-1","first-page":"563784","volume-title":"Huntington's disease: An immune perspective","author":"Nayak","year":"2011","journal-title":"Neurol Res Int"},{"key":"key-10.4103\/2394-8108.192519-2","first-page":"1","volume-title":"Scientific approaches to Huntington's disease","author":"Sanberg","year":"1984","journal-title":"CRC Crit Rev Clin Neurobiol"},{"key":"key-10.4103\/2394-8108.192519-3","first-page":"585","volume-title":"Impairment of rapid movement in Huntington's disease","author":"Hefter","year":"1987","journal-title":"Brain"},{"key":"key-10.4103\/2394-8108.192519-4","first-page":"971","volume-title":"The Huntington's Disease Collaborative Research Group","author":"A","year":"1993","journal-title":"Cell"},{"key":"key-10.4103\/2394-8108.192519-5","first-page":"287","volume-title":"Reversal of long-term locomotor abnormalities in the kainic acid model of Huntington's disease by day 18 fetal striatal implants","author":"Deckel","year":"1983","journal-title":"Eur J Pharmacol"},{"key":"key-10.4103\/2394-8108.192519-6","first-page":"813","volume-title":"Striatal grafts in rats with unilateral neostriatal lesions \u2013 III.Recovery from dopamine-dependent motor asymmetry and deficits in skilled paw reaching","author":"Dunnett","year":"1988","journal-title":"Neuroscience"},{"key":"key-10.4103\/2394-8108.192519-7","first-page":"2728","volume-title":"Graft-induced behavioral recovery in an animal model of Huntington disease","author":"Isacson","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/2394-8108.192519-8","first-page":"211","volume-title":"Human neural stem cell transplants improve motor function in a rat model of Huntington's disease","author":"McBride","year":"2004","journal-title":"J Comp Neurol"},{"key":"key-10.4103\/2394-8108.192519-9","first-page":"1187","volume-title":"Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease","author":"Roberts","year":"2006","journal-title":"Neuroscience"},{"key":"key-10.4103\/2394-8108.192519-10","first-page":"16707","volume-title":"Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats","author":"Aubry","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/2394-8108.192519-11","first-page":"96","volume-title":"Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: Trophic and tropic effects in a rodent model of Huntington's disease","author":"Kordower","year":"1997","journal-title":"J Comp Neurol"},{"key":"key-10.4103\/2394-8108.192519-12","first-page":"194","volume-title":"Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease","author":"Bachoud-L\u00e9vi","year":"2000","journal-title":"Exp Neurol"},{"key":"key-10.4103\/2394-8108.192519-13","first-page":"1975","volume-title":"Motor and cognitive improvements in patients with Huntington's disease after neural transplantation","author":"Bachoud-L\u00e9vi","year":"2000","journal-title":"Lancet"},{"key":"key-10.4103\/2394-8108.192519-14","first-page":"13877","volume-title":"Transplanted fetal striatum in Huntington's disease: Phenotypic development and lack of pathology","author":"Freeman","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/2394-8108.192519-15","first-page":"687","volume-title":"Bilateral human fetal striatal transplantation in Huntington's disease","author":"Hauser","year":"2002","journal-title":"Neurology"},{"key":"key-10.4103\/2394-8108.192519-16","first-page":"30","volume-title":"Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation","author":"Gallina","year":"2010","journal-title":"Exp Neurol"},{"key":"key-10.4103\/2394-8108.192519-17","first-page":"303","volume-title":"Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: A long-term follow-up study","author":"Bachoud-L\u00e9vi","year":"2006","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/2394-8108.192519-18","first-page":"948","volume-title":"Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease","author":"Reuter","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/2394-8108.192519-19","first-page":"116","volume-title":"Creatine kinase: An enzyme with a central role in cellular energy metabolism","author":"Wallimann","year":"1998","journal-title":"MAGMA"},{"key":"key-10.4103\/2394-8108.192519-20","first-page":"229","volume-title":"Some new aspects of creatine kinase (CK): Compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology","author":"Wallimann","year":"1998","journal-title":"Biofactors"},{"key":"key-10.4103\/2394-8108.192519-21","first-page":"329","volume-title":"Functions and effects of creatine in the central nervous system","author":"Andres","year":"2008","journal-title":"Brain Res Bull"},{"key":"key-10.4103\/2394-8108.192519-22","first-page":"385","volume-title":"Mitochondrial defect in Huntington's disease caudate nucleus","author":"Gu","year":"1996","journal-title":"Ann Neurol"},{"key":"key-10.4103\/2394-8108.192519-23","first-page":"5110","volume-title":"Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine","author":"Calabresi","year":"2001","journal-title":"J Neurosci"},{"key":"key-10.4103\/2394-8108.192519-24","first-page":"1193","volume-title":"CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain","author":"Aronin","year":"1995","journal-title":"Neuron"},{"key":"key-10.4103\/2394-8108.192519-25","first-page":"1913","volume-title":"The effects of creatine supplementation on striatal neural progenitor cells depend on developmental stage","author":"Andres","year":"2016","journal-title":"Amino Acids"},{"key":"key-10.4103\/2394-8108.192519-26","first-page":"33","volume-title":"Effects of creatine treatment on survival and differentiation of GABA-ergic neurons in cultured striatal tissue","author":"Andres","year":"2005","journal-title":"J Neurochem"},{"key":"key-10.4103\/2394-8108.192519-27","first-page":"2","volume-title":"Creatine improves the metabolic state of murine and human neural stem cells and improves expansion and neuronal induction","author":"Andres","year":"2010","journal-title":"Regen Med"},{"key":"key-10.4103\/2394-8108.192519-28","first-page":"925","volume-title":"Creatine supplementation in Huntington's disease: A placebo-controlled pilot trial","author":"Verbessem","year":"2003","journal-title":"Neurology"},{"key":"key-10.4103\/2394-8108.192519-29","first-page":"250","volume-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"key-10.4103\/2394-8108.192519-30","first-page":"850","volume-title":"PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease","author":"Rosas","year":"2014","journal-title":"Neurology"},{"key":"key-10.4103\/2394-8108.192519-31","first-page":"1327","volume-title":"The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain","author":"Ohtsuki","year":"2002","journal-title":"J Cereb Blood Flow Metab"},{"key":"key-10.4103\/2394-8108.192519-32","first-page":"242","volume-title":"Risk assessment for creatine monohydrate","author":"Shao","year":"2006","journal-title":"Regul Toxicol Pharmacol"},{"key":"key-10.4103\/2394-8108.192519-33","first-page":"230","volume-title":"Brain energy metabolism in Alzheimer's disease: 99mTc-HMPAO SPECT imaging during verbal fluency and role of astrocytes in the cellular mechanism of 99mTc-HMPAO retention","author":"Slosman","year":"2001","journal-title":"Brain Res Brain Res Rev"},{"key":"key-10.4103\/2394-8108.192519-34","first-page":"164","volume-title":"Mitochondrial creatine kinase in human health and disease","author":"Schlattner","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"key-10.4103\/2394-8108.192519-35","first-page":"2520","volume-title":"Oxidative modification of creatine kinase BB in Alzheimer's disease brain","author":"Aksenov","year":"2000","journal-title":"J Neurochem"},{"key":"key-10.4103\/2394-8108.192519-36","doi-asserted-by":"crossref","unstructured":"Wallimann T, Tokarska-Schlattner M, Neumann D, Epand RM, Epand RF, Hornemann T, et. al. The phosphocreatine circuit: Molecular and cellular physiology of creatine kinases, sensitivity to free radicals, and enhancement by creatine supplementation. In: Saks V, editor. Molecular System Bioenergetics: Energy for Life. Weinheim: Wiley-VCH Verlag GmbH & Co.; 2007. p. 195-264.","DOI":"10.1002\/9783527621095.ch7"},{"key":"key-10.4103\/2394-8108.192519-37","unstructured":"Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The Genetic Basis of Human Cancer. New York: McGraw-Hill; 2002. p. 93-113."},{"key":"key-10.4103\/2394-8108.192519-38","first-page":"502","volume-title":"Mitochondria, oxygen free radicals, disease and ageing","author":"Raha","year":"2000","journal-title":"Trends Biochem Sci"},{"key":"key-10.4103\/2394-8108.192519-39","first-page":"143","volume-title":"Creatine deficiency syndromes","author":"Schulze","year":"2003","journal-title":"Mol Cell Biochem"},{"key":"key-10.4103\/2394-8108.192519-40","first-page":"742","volume-title":"Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease","author":"Lin","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"key-10.4103\/2394-8108.192519-41","first-page":"35936","volume-title":"The creatine kinase\/creatine connection to Alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine deposits","author":"B\u00fcrklen","year":"2006","journal-title":"J Biomed Biotechnol"},{"key":"key-10.4103\/2394-8108.192519-42","first-page":"9810","volume-title":"Ammonium-induced impairment of axonal growth is prevented through glial creatine","author":"Braissant","year":"2002","journal-title":"J Neurosci"},{"key":"key-10.4103\/2394-8108.192519-43","first-page":"1777","volume-title":"Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain","author":"Andres","year":"2011","journal-title":"Brain"},{"key":"key-10.4103\/2394-8108.192519-44","first-page":"50","volume-title":"Creatine promotes the GABAergic phenotype in human fetal spinal cord cultures","author":"Ducray","year":"2007","journal-title":"Brain Res"},{"key":"key-10.4103\/2394-8108.192519-45","first-page":"1075","volume-title":"Dynamic expression pattern of distinct genes in the presomitic and somitic mesoderm during Xenopus development","author":"Bourdelas","year":"2009","journal-title":"Int J Dev Biol"},{"key":"key-10.4103\/2394-8108.192519-46","first-page":"271","volume-title":"Effect of embryonic donor age and dissection on the DARPP-32 content of cell suspensions used for intrastriatal transplantation","author":"Watts","year":"1997","journal-title":"Exp Neurol"},{"key":"key-10.4103\/2394-8108.192519-47","first-page":"85","volume-title":"Embryonic donor age and dissection influences striatal graft development and functional integration in a rodent model of Huntington's disease","author":"Watts","year":"2000","journal-title":"Exp Neurol"},{"key":"key-10.4103\/2394-8108.192519-48","first-page":"156","volume-title":"Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease","author":"Matthews","year":"1998","journal-title":"J Neurosci"},{"key":"key-10.4103\/2394-8108.192519-49","first-page":"1359","volume-title":"Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice","author":"Dedeoglu","year":"2003","journal-title":"J Neurochem"},{"key":"key-10.4103\/2394-8108.192519-50","first-page":"4389","volume-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease","author":"Ferrante","year":"2000","journal-title":"J Neurosci"},{"key":"key-10.4103\/2394-8108.192519-51","first-page":"1833","volume-title":"Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats","author":"Shear","year":"2000","journal-title":"Neuroreport"},{"key":"key-10.4103\/2394-8108.192519-52","first-page":"701","volume-title":"Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue","author":"Andres","year":"2005","journal-title":"Neuroscience"},{"key":"key-10.4103\/2394-8108.192519-53","first-page":"537","volume-title":"Creatine supplementation improves dopaminergic cell survival and protects against MPP+ toxicity in an organotypic tissue culture system","author":"Andres","year":"2005","journal-title":"Cell Transplant"},{"key":"key-10.4103\/2394-8108.192519-54","first-page":"1968","volume-title":"Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons","author":"Brewer","year":"2000","journal-title":"J Neurochem"},{"key":"key-10.4103\/2394-8108.192519-55","first-page":"347","volume-title":"Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis","author":"Klivenyi","year":"1999","journal-title":"Nat Med"},{"key":"key-10.4103\/2394-8108.192519-56","first-page":"576","volume-title":"Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis","author":"Klivenyi","year":"2004","journal-title":"J Neurochem"},{"key":"key-10.4103\/2394-8108.192519-57","first-page":"11159","volume-title":"Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model","author":"Dupuis","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/2394-8108.192519-58","first-page":"267","volume-title":"Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS","author":"Zhang","year":"2003","journal-title":"Ann Neurol"}],"container-title":["Brain Circulation"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:28:39Z","timestamp":1786714119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2394-8108.192519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"alternative-id":["192519"],"URL":"https:\/\/doi.org\/10.4103\/2394-8108.192519","relation":{},"ISSN":["2394-8108"],"issn-type":[{"value":"2394-8108","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}